Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 289–312 of 328
Telomir-Zn reactivates tumor suppressors with 50-fold selectivity
Telomir-Zn, a compound that modulates intracellular iron and copper to inhibit histone demethylases, suppressed tumor growth in preclinical prostate and triple-negative breast cancer models while maintaining a 50-fold selectivity window favoring normal cell survival. The mechanism reactivated silenced tumor-suppressor genes and showed synergistic effects with standard chemotherapy in select cancer lines, supporting advancement to clinical trials.
A hierarchy of causes of death in senescent C. elegans
Research in senescent C. elegans reveals a hierarchical cascade of organ system failures rather than simultaneous deterioration, with specific tissues failing in sequence as aging progresses. This finding clarifies the mechanistic order of senescent decline and suggests that interventions targeting early failures in this cascade may prevent downstream system collapse.
#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.
CD47 Platelets Suppress Aging Inflammation in Centenarians
Centenarians carry genetic and platelet-based mechanisms that suppress age-related inflammation through CD47 expression, which dampens monocyte activation. The LAV-BPIFB4 variant drives this protective effect, and recombinant administration of the protein replicates these benefits in non-carriers, establishing a translatable therapeutic target for inflammaging and cardiovascular disease.
CorTec receives FDA breakthrough device designation
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
NK Cell Therapy Targets Neurodegeneration Beyond Alzheimer's
NkGen Biotech will present Troculeucel, a cryopreserved autologous NK cell therapy, at BIOCHINA 2026, with Phase 2 trials underway for Alzheimer's disease and potential expansion into ALS, frontotemporal dementia, and Parkinson's disease. The therapy represents a cell-based approach to neurodegenerative conditions where conventional pharmacology has shown limited efficacy.
CFTR Protein Blocks Heart Cell Aging Through Calcium Control
CFTR, a protein typically studied for its ion channel function, operates through a secondary mechanism to prevent cardiomyocyte senescence by reducing mitochondrial oxidative stress. The USP45 enzyme stabilizes CFTR through deubiquitination, which enhances calcium regulation and protects heart cells from age-related dysfunction implicated in atrial fibrillation and cardiovascular disease.
Biophytis-LynxKite AI alliance broadens longevity drug pipeline
Biophytis and LynxKite are expanding their AI-driven drug discovery partnership beyond sarcopenia to build a broader platform for age-related diseases, including dry age-related macular degeneration. The alliance demonstrates a concrete application of AI to accelerate candidate identification and reduce development timelines in longevity therapeutics.
Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy
Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.
NorthStrive addresses muscle loss with EL-22 patent
NorthStrive Biosciences filed a patent for EL-22, a myostatin-engineered probiotic designed to prevent muscle loss in GLP-1 users, aging populations, and post-injury recovery. The filing addresses a critical gap in weight-loss and longevity interventions: preserving muscle composition rather than optimizing weight loss alone.
#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration
This AMA addresses multiple dimensions of disease prevention and optimization: family history assessment as a risk stratification tool, cardiovascular disease prevention through metabolic and behavioral intervention, strength training efficiency for maintaining muscle mass and metabolic function, dementia risk reduction through modifiable factors, NAD supplementation's role in cellular energy production, and hydration's foundational importance to physiological function. The aggregate effect of these interventions addresses primary prevention across multiple chronic disease pathways relevant to longevity.
UDCA Restores Egg Quality by Reactivating Mitochondrial Repair
Ursodeoxycholic acid (UDCA), a clinically available compound, restores mitochondrial quality in aged oocytes by upregulating EGR1, a transcription factor that coordinates cellular cleanup mechanisms. This identifies a tractable molecular pathway for addressing reproductive aging at its regulatory source rather than at the level of downstream dysfunction.
RORA-PRNP Axis Triggers Age-Related Cataracts via Senescence
RORA, a transcription factor, exacerbates age-related cataract by targeting the prion protein (PRNP) and triggering oxidative stress-induced senescence and apoptosis in lens epithelial cells. Inhibiting RORA or blocking the RORA-PRNP axis restores cellular resilience and may offer a therapeutic target for cataract prevention and reversal.
Mitochondrial Therapy FORZINITY Gains FDA Approval for Barth Syndrome
Stealth BioTherapeutics rebranded as Mighty Therapeutics following FDA accelerated approval of FORZINITY (elamipretide), the first FDA-approved therapy directly targeting mitochondrial function for Barth syndrome. The approval represents a significant milestone in mitochondrial medicine, with the company pursuing expanded indications in younger patients and age-related macular degeneration.
BioAge Labs Provides Business Updates
BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.
Alpha-Klotho Manufacturing Milestone Clears Path to Clinic
Avaí Bio has completed a Good Manufacturing Practice Master Cell Bank for alpha-Klotho therapy, establishing the standardized cellular foundation required for consistent clinical-scale production. This manufacturing milestone addresses a critical bottleneck in longevity biotechnology: translating promising discoveries into reliably produced treatments.
Association Between Vitamins and Slower Biological Aging
A large epidemiological analysis of 15,050 participants found that higher intake of vitamins, particularly C and B2, correlates with slower biological aging as measured by multiple aging biomarkers. The association remained significant after adjustment for socioeconomic and lifestyle factors, suggesting a direct relationship between vitamin adequacy and the rate of biological aging.
SIRT5 Loss Drives Neuronal Death Through Mitochondrial Fission Dysregulation
SIRT5 downregulation in Alzheimer's disease permits excessive succinylation of HNRNPC, which stabilizes and upregulates YME1L1, disrupting mitochondrial fission-fusion balance and triggering neuronal death. Restoring SIRT5 activity reverses this cascade in mouse models, suggesting a targetable pathway for AD intervention.
Cognito and Ochsner launch brain health collaboratory
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.
Rubedo Announces Positive Preliminary Results for RLS-1496
Rubedo's RLS-1496, a GPX4 modulator designed to target senescent cells, met primary safety endpoints in a Phase 1 trial and demonstrated dose-dependent clinical improvements in psoriasis, atopic dermatitis, and photoaged skin within four weeks. The compound showed reduced senescent cell burden, decreased inflammatory markers, and increased collagen expression with no serious adverse events.
Neurotrophic Signaling Drug Passes Safety Threshold for Dementia
AlzeCure's ACD856 completed Phase Ib trials with safety clearance and demonstrated adequate central nervous system penetration at higher doses, establishing dosing parameters for Phase II studies in Alzheimer's disease and depression. The compound's mechanism—enhancing neurotrophic signaling and reducing neuroinflammation—addresses two conditions sharing common pathological underpinnings in neurodegeneration.
Aging‐Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
TDP-43 targeting restores neuronal energy and extends ALS survival
Researchers identified a specific toxic region within TDP-43 protein and developed a small molecule that crosses the blood-brain barrier to target it, demonstrating improved mitochondrial function, reduced neuronal death, and extended survival in ALS models. This represents a mechanistic advance in addressing a protein dysfunction central to multiple neurodegenerative diseases.
Noom buys pharmacy to push into healthy aging
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy operating across 46 states, to integrate prescription-grade therapies with behavioral coaching and establish a comprehensive preventive care platform. This move positions the company to expand beyond weight management into broader healthy aging interventions including peptide therapies and metabolic support.